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Objective: This study assessed the effi-
cacy of olanzapine in delaying or prevent-
ing conversion to psychosis and reducing
symptoms in people with prodromal
symptoms of schizophrenia.
Method: This randomized trial occurred
at four North American clinics in the Pre-
vention Through Risk Identification, Man-
agement, and Education project. Outpa-
tients received olanzapine (5–15 mg/day,
N=31) or placebo (N=29) during a 1-year
double-blind treatment period and no
treatment during a 1-year follow-up pe-
riod. Efficacy measures included the con-
version-to-psychosis rate and Scale of Pro-
dromal Symptoms scores.
Results: During the treatment year,
16.1% of olanzapine patients and 37.9%
of placebo patients experienced a conver-
sion to psychosis, a nearly significant dif-
ference. The hazard of conversion among
placebo patients was about 2.5 times that
among olanzapine-treated patients,
which also approached significance. In
the follow-up year, the conversion rate
did not differ significantly between
groups. During treatment, the mean
score for prodromal positive symptoms
improved more in the olanzapine group
than in the placebo group, and the
mixed-model repeated-measures least-
squares mean score showed significantly
greater improvement between weeks 8
and 28 with olanzapine. The olanzapine
patients gained significantly more weight
(mean=8.79 kg, SD=9.05, versus mean=
0.30 kg, SD=4.24).
Conclusions: A significant treatment dif-
ference in the conversion-to-psychosis
rate was not demonstrated. However,
these results may be influenced by low
power. The nearly significant differences
suggest that olanzapine might reduce the
conversion rate and delay onset of psy-
chosis. Olanzapine was efficacious for
positive prodromal symptoms but in-
duced weight gain. Further treatment re-
search in this phase of illness is war-
ranted.
(Am J Psychiatry 2006; 163:790–799)
The chronicity of schizophrenia determines the pri-
mary rationale for studies of early detection and early in-
tervention for this disorder. A preventive approach was
suggested many years ago (1), but not until developments
in the last decade has it proven feasible, ethical, and at-
tractive from a risk-benefit perspective (2). These develop-
ments include the introduction of atypical antipsychotics
and the ability to identify with reasonable psychometric
precision, reliability, and predictive validity persons at
high risk for psychosis in the early (prodromal) phases of
schizophrenia (3).
Despite the importance of prodromal intervention
studies in schizophrenia, to our knowledge only three ran-
domized studies have been conducted to date (3–7). The
first study, by McGorry et al. (4), was a randomized clinical
trial of patients meeting criteria for high risk and prodro-
mal symptoms (8, 9) and provides the strongest evidence
to date of the efficacy and safety of early intervention. In
addition to the needs-based intervention, the experimen-
tal group in this study received open-label risperidone (1–
2 mg/day) plus cognitive behavior stress management for
6 months, followed by 6 months of no treatment. The con-
trol group received needs-based intervention only. The
second study, a randomized trial of cognitive behavior
therapy conducted by Morrison et al. (5), suggests that
psychosocial treatment alone may prevent or delay the
onset of schizophrenia. The third study, presented in the
current report, is to our knowledge the first double-blind,
placebo-controlled clinical trial of an atypical antipsy-
chotic, olanzapine, for patients with prodromal symptoms
of schizophrenia at high risk for psychosis.
The study objectives were to determine whether olanza-
pine can delay or prevent the onset of psychosis and re-
duce prodromal symptoms with adequate safety. The cur-
rent report focuses on the effects of olanzapine during the
double-blind treatment year and the follow-up (no-treat-
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ment) year. Three previously published reports detail the
study rationale and design (3), the recruitment procedures
and baseline characteristics of the prodromal study group
(6), and the efficacy and safety of olanzapine versus pla-
cebo in the first 8 weeks of the double-blind period (7).
Briefly, the study included help-seeking persons be-
tween ages 12 and 45 years who responded to advertise-
ments or who were referred by clinicians. Persons meeting
the study criteria for the prodrome were told that they had
symptoms suggesting an increased risk of developing psy-
chosis. They were informed of the study and invited to
consent to participate. Excluded were persons who met
the criteria for a past or current psychotic disorder, who
had a treatable psychiatric disorder that could account for
the prodromal symptoms, who were suicidal or homicidal,
or whose prodromal symptoms were primarily sequelae of
drug or alcohol use.
The study consisted of four periods: 1) 3- to 14-day screen-
ing, 2) a 1-year period of double-blind treatment with olan-
zapine (5–15 mg/day) or placebo, 3) a 1-year no-treatment
follow-up period, and 4) a 6-month period of open-label
treatment with olanzapine (5–10 mg/day) for patients who
experienced a conversion to psychosis. This report focuses
on study periods 2 (double-blind treatment) and 3 (no-treat-
ment follow-up). In period 2, the study drug consisted of 5-
mg olanzapine tablets or placebo tablets dispensed in blister
packs that allowed monitoring of drug compliance. Con-
comitant psychoactive medications were not allowed, and
supportive psychosocial interventions were available to all
patients and their families.
Before being randomly assigned to a study drug, each pa-
tient signed an informed consent form. The study protocol
was approved by the appropriate institutional review boards.
Method
This study was conducted from 1997 to 2003 at the Prevention
Through Risk Identification, Management, and Education
(PRIME) clinics at four sites: Yale University, New Haven, Conn.
(T.H.M., primary investigator); University of Toronto, Toronto
(R.B.Z., primary investigator); University of North Carolina,
Chapel Hill (D.P., primary investigator); and University of Calgary,
Calgary, Alta., Canada (J.A., primary investigator).
In this article, “the prodrome to onset of psychosis” refers to a
virtual syndrome that is validated only after the onset; thus, the
term “prodromal” here means “putatively prodromal.” We used
the Structured Interview for Prodromal Syndromes (10, 11) to de-
termine whether the patients met the Criteria for Prodromal Syn-
dromes (12). In turn, the Criteria for Prodromal Syndromes (de-
tailed in references 3, 12, and 13) operationally define the three
prodromal syndromes outlined by Yung and McGorry (8): attenu-
ated positive symptom syndrome, genetic risk and deterioration
syndrome, and brief intermittent psychotic state syndrome.
Assessments
The primary efficacy measure for study periods 2 and 3 was the
rate of conversion to psychosis. “Psychosis” was defined as psy-
chotic disorders in the DSM-IV schizophrenia spectrum and was
identified by using the Presence of Psychosis Scale (3), which we
developed because of the lack of DSM-IV-defined criteria for psy-
chosis onset.
The secondary efficacy measures assessed changes in prodro-
mal symptoms, schizophrenia symptoms, and patients’ function-
ing and included the Scale of Prodromal Symptoms (10, 13), Pos-
itive and Negative Syndrome Scale (PANSS) (14), Clinical Global
Impression (CGI) severity of illness scale (15, pp. 218–222), Mont-
gomery-Åsberg Depression Rating Scale (MADRS) (16), Young
Mania Rating Scale (17), and Global Assessment of Functioning
Scale (GAF) (18). The Scale of Prodromal Symptoms, developed in
1997 by the senior author and colleagues, includes 19 items that
assess positive symptoms, negative symptoms, disorganization
symptoms, and general symptoms. All of the items are rated from
0 to 6: 0=not present, 3=moderate, 5=severe but not psychotic, 6=
severe and psychotic. The Scale of Prodromal Symptoms is em-
bedded within the Structured Interview for Prodromal Syn-
dromes, which was designed to diagnose prodromal syndromes
according to the criteria mentioned earlier (3, 8, 13) and to rate
the severity of prodromal symptoms.
Vital sign measurements, laboratory tests, and electrocardio-
grams were performed during both study periods. Extrapyrami-
dal symptoms and abnormal involuntary movements were as-
sessed during study period 2 by using the Simpson-Angus Rating
Scale (19), Abnormal Involuntary Movement Scale (15, pp. 534–
537), and Barnes Rating Scale for Drug-Induced Akathisia (20).
TABLE 1. Baseline Characteristics of Patients With Prodromal Psychotic Symptoms Who Received Treatment With Olanza-
pine or Placebo
Characteristic
Placebo 
(N=29)
Olanzapine 
(N=31)
Difference Between 
Groups
Mean SD Mean SD ANOVA (p)a
Age (years) 17.2 4.0 18.2 5.5 0.45
N % N % Fisher’s exact test (p)
Male 18 62.1 21 67.7 0.79
Caucasian 17 58.6 23 74.2 0.27
Married 1 3.4 1 3.2 1.00
Serious mental illness in first-degree relativesb
Psychosis 5 17.2 8 26.7 0.38
Nonpsychotic major depression 8 27.6 2 6.7 0.04
Nonpsychotic bipolar disorder 1 3.4 1 3.3 0.99
Current substance abuse or dependence
Marijuana 1 3.4 3 9.7 0.61
Alcohol 0 0.0 1 3.2 1.00
a Analysis of variance with effects for treatment and investigator (F=0.57, df=1, 55).
b Measured with the Modified Family History Research Diagnostic Criteria (22). N=30 for the olanzapine group.
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Premorbid functioning was measured with the Cannon-Spoor
Premorbid Adjustment Scale (21), and family history of mental ill-
ness was assessed with the Modified Family History Research Di-
agnostic Criteria (22). Finally, each patient was thoroughly inter-
viewed at the initial evaluation to determine the presence of
current or past axis I and axis II disorders.
Statistical Analyses
All analyses were done on an intent-to-treat basis. All cited p
values were two-sided with a significance level of 0.05. The
planned primary analysis was to use the Fisher exact test to assess
treatment differences in the conversion-to-psychosis rates dur-
ing study periods 2 and 3 among those who completed the study
or converted to psychosis. For the analyses in this report, the de-
nominators for the conversion rates during study periods 2 and 3
are the total numbers of patients who entered these study peri-
ods. In retrospect, the Fisher exact test was not equipped to han-
dle the varying durations of study participation that resulted from
a high dropout rate and the variable timing of conversion to psy-
chosis. A post hoc analysis of the Cox proportional hazards model
of the data on time to onset of psychosis is included in this report
to supplement the results from the primary analysis because this
survival analysis was deemed more capable of handling right-
censored observations, of accounting for the timing of the events,
and of evaluating the primary efficacy measure. This Cox propor-
tional hazards model included treatment and baseline scores for
positive symptoms on the Scale of Prodromal Symptoms as the
terms in the model. The score for prodromal positive symptoms
was included in the model because positive symptoms as mea-
sured by the Scale of Prodromal Symptoms were used to define
psychosis and conversion to psychosis.
Analysis of covariance (ANCOVA) was used to evaluate the
changes in continuous efficacy variables during study period 2,
based on the last observation carried forward. Analysis of vari-
ance (ANOVA) was used to evaluate such changes during study
period 3 and changes in continuous safety variables during both
study periods, with the last observation carried forward. ANCOVA
models included terms for treatment group, investigator, and
baseline value; the ANOVA models included terms for treatment
group and investigator. For all analyses of continuous variables,
last observation carried forward was used as the analytical proto-
col-defined method to handle missing data in the analyses of
mean change. Since the development of this study protocol, this
method has been documented to result in biased treatment esti-
mates and their standard errors when the data violate the follow-
ing assumptions: 1) data missing at random and 2) subject re-
sponses being constant from the last observed value to the
endpoint of the trial. This bias can result in the inflation of type I
error when the treatments do not show different outcomes and
overestimation of the magnitude of treatment differences when
the treatments do show different outcomes. For this reason, we
employed an alternative analysis using a mixed-effects model re-
peated-measures ANCOVA to analyze the change from baseline
to each postbaseline visit in the positive symptom score on the
Scale of Prodromal Symptoms (23). A first-order autoregressive
moving-average covariance matrix was determined by Akaike’s
information criterion to be the best-fit covariance structure in
modeling the within-patient error. The ANCOVA model included
the categorical variables of investigator, treatment group, week of
therapy, and interaction of treatment and week of therapy and the
continuous covariate of baseline score as fixed effects.
Categorical data, which included demographic and illness
characteristics, discontinuation rate, treatment-emergent ad-
verse events, and treatment-emergent extrapyramidal symptoms,
were evaluated by using Fisher’s exact test.
Results
Baseline Patient and Illness Characteristics
Sixty treatment-seeking patients with prodromal symp-
toms were recruited across the four sites. The overall study
group was largely Caucasian (66.7%, N=40), young (me-
dian age=16 years, range=12–36), male (65.0%, N=39), and
single (91.7%, N=55). Our second report (6) details the
overall patient characteristics.
Table 1 shows the distribution of demographic and ill-
ness characteristics in the two treatment groups. The only
significant difference was in the rate of family history of
nonpsychotic depression, which was higher in the pla-
cebo group. Compliance with the study drug regimen dur-
ing study period 2 did not differ significantly between
groups (data not shown).
Dropouts and Conversions to Psychosis
Table 2 presents the rates of patients who dropped out
or whose symptoms converted to psychosis during each
study period. During study period 2, the dropout rate for
reasons other than conversion to psychosis was higher for
the olanzapine group, but this did not differ significantly
between treatment groups. In addition, no significant dif-
ference was observed in the rate of patients who discon-
tinued this study period because of adverse events: 3.4%
in the placebo group (one of 29) and 3.2% in the olanza-
pine group (one of 31).
During this period the rate of conversion to psychosis
was higher for placebo, but the group difference was not
significant (Table 2). All five of the olanzapine-treated pa-
tients who converted to psychosis did so within the first 4
TABLE 2. Rates of Conversion to Psychosis and Other Treatment Discontinuation Among Patients With Prodromal Psy-
chotic Symptoms During 1 Year of Treatment With Olanzapine or Placebo and 1 Year of Follow-Up
Patients Who Dropped Out for Reasons Other 
Than Conversion to Psychosis Conversion to Psychosis
Study Period and Treatment Group N %
Fisher’s Exact 
Test (p) N %
Fisher’s Exact 
Test (p)
Double-blind treatment 0.13 0.08
Placebo group (N=29) 10 34.5 11 37.9
Olanzapine group (N=31) 17 54.8 5 16.1
Total (N=60) 27 45.0 16 26.7
No-treatment follow-up period 1.00
Former placebo group (N=8) 0 0.0 2 25.0
Former olanzapine group (N=9) 0 0.0 3 33.3
Total (N=17) 0 0.0 5 29.4
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weeks, whereas the 11 placebo-treated patients converted
to psychosis throughout the entire year. Kaplan-Meier sur-
vival curves of the time to onset of psychosis during study
period 2 are plotted in Figure 1. Results from the Cox pro-
portional hazards model showed that the treatment groups
differed to a nearly significant degree (p=0.09) in the hazard
of converting to psychosis after adjustment for the baseline
severity of positive prodromal symptoms: the hazard of
conversion to psychosis for the placebo-treated patients
was 2.5 times that for the olanzapine-treated patients.
Overall, 12 of the 60 patients (20.0%) completed both
periods of the study. The overall rate of conversion to psy-
chosis was 35.0% (21 of 60).
During study period 3, there were no discontinuations
due to any reasons other than conversion to psychosis in
either treatment group. Because of the low number of pa-
tients who entered this study period, no statistical analysis
was performed to assess treatment differences in the time
to onset of psychosis during this study period.
Efficacy for Prodromal Symptoms and Severity 
of Illness
Table 3 shows patients’ changes in symptom and func-
tioning scores during the double-blind treatment. The
groups did not differ significantly in mean baseline-to-
endpoint changes (last observation carried forward) in
these scores. However, the olanzapine group showed a
greater improvement in positive symptoms than the pla-
cebo group, and the difference approached significance.
Significant baseline-to-endpoint changes were seen in the
total score and positive symptom score on the Scale of
Prodromal Symptoms within the olanzapine group and in
the GAF current score within the olanzapine and placebo
groups. The ratings of psychosis (PANSS), depression
(MADRS), and mania (Young Mania Rating Scale) changed
little in either group.
Figure 2 shows the mixed-effects model repeated-mea-
sures least-squares mean change in positive symptoms on
the Scale of Prodromal Symptoms for the olanzapine and
placebo groups at each postbaseline visit during study pe-
riod 2. The overall treatment effect (F=5.21, df=1, 53,
p<0.03) and the week-of-therapy effect (F=1.76, df=17,
555, p<0.03) were both significant, indicating that overall
there were significant differences between treatment
groups and that the positive symptom score significantly
changed over time. The interaction of treatment and week
of therapy was not significant (F=1.25, df=17, 555, p=0.22),
indicating that the treatment differences did not signifi-
cantly change over time. The only significant between-
treatment differences were observed between weeks 8 and
28, when the least-squares mean changes in positive
symptom scores were significantly greater for the olanza-
pine patients.
In study period 3 (the no-treatment follow-up), positive
symptom scores on the Scale of Prodromal Symptoms
worsened significantly for the nine patients from the
former olanzapine group (baseline at end of treatment
phase: mean=5.33, SD=5.43; change from baseline: mean=
5.22, SD=5.85) (Wilcoxon signed-rank test, T=16.5, N=9,
p=0.02). For the eight patients from the former placebo
group, positive prodromal symptoms also worsened in
this study period but not significantly (baseline for study
period: mean=3.63, SD=3.93; change from baseline:
mean=2.88, SD=8.61) (p=0.61, Wilcoxon signed-rank test).
FIGURE 1. Time to Onset of Psychosis Among Patients With
Prodromal Psychotic Symptoms During 1 Year of Treat-
ment With Olanzapine or Placeboa
a Observations for subjects who dropped out were censored.
P
ro
p
o
rt
io
n
 W
it
h
o
u
t 
P
sy
ch
o
si
s
Day
1.0
0.8
0.6
0.4
0.2
0.0
0 100 200 300 400
Olanzapine (N=31)
Placebo (N=29)
Censored
observation
FIGURE 2. Change in Positive Symptoms Among Patients
With Prodromal Psychotic Symptoms During 1 Year of
Treatment With Olanzapine or Placeboa
a Mixed-effects model repeated-measures analysis.
b Significant difference between groups (p<0.05).
Le
a
st
-S
q
u
a
re
s 
M
e
a
n
 C
h
a
n
ge
 i
n
 S
co
re
 f
o
r 
P
o
si
ti
ve
Sy
m
p
to
m
s 
o
n
 S
ca
le
 o
f 
P
ro
d
ro
m
a
l 
Sy
m
p
to
m
s
Week
2
1
0
–2
–4
–6
–1
–3
–5
0 12 24 36 484 16 28 32 408 20 44
Olanzapine (N=31)
Placebo (N=29)
b b
b b
b
b b
794 Am J Psychiatry 163:5, May 2006
OLANZAPINE IN PRODROMALLY SYMPTOMATIC PATIENTS
ajp.psychiatryonline.org
Safety
During study period 2, there were no significant differ-
ences between treatment groups in mean baseline-to-
endpoint changes for extrapyramidal symptoms, in the
proportion of patients with treatment-emergent extrapy-
ramidal symptoms, or in the proportion of patients with
normal baseline ECG results and abnormal postbaseline
results. Of 35 laboratory test results analyzed, there were
no values out of the normal range for either group, includ-
ing values for blood glucose and cholesterol. There were
significant differences between groups in mean baseline-
to-endpoint changes (with the last observation carried
forward) for five measures during study period 2: alkaline
phosphatase (F=5.96, df=1, 50, p=0.02), γ-glutamyltrans-
ferase (F=6.29, df=1, 50, p=0.02), hematocrit (F=4.50, df=1,
47, p=0.04), inorganic phosphorus (F=5.30, df=1, 48, p=
0.03), and uric acid (F=7.96, df=1, 50, p=0.007). There were
significant differences between groups in changes on two
measures during study period 3: γ-glutamyltransferase (F=
6.07, df=1, 14, p=0.03) and lymphocyte count (F=5.95, df=
TABLE 3. Changes in Psychopathology of Patients With Prodromal Psychotic Symptoms During 1 Year of Treatment With
Olanzapine or Placebo
Measure
Placebo (N=29)a
Baseline Change From Baselinec
Paired t Test for Change 
Within Group
Mean SD Mean SD t (df=28) p
Scale of Prodromal Symptoms scores
Total 38.59 14.46 –2.03 19.08 –0.57 0.57
Positive symptoms 9.62 4.30 0.31 7.60 0.22 0.83
Negative symptoms 14.83 7.06 –1.31 6.54 –1.08 0.29
Disorganization 6.28 3.67 0.21 4.54 0.25 0.81
General symptoms 7.86 4.02 –1.24 4.21 –1.59 0.12
Positive and Negative Syndrome Scale scores
Total 63.28 16.72 –1.83 21.65 –0.45 0.65
Positive symptoms 13.31 3.52 0.86 6.74 0.69 0.50
Negative symptoms 17.21 6.81 –0.76 5.66 –0.72 0.48
General symptoms 32.76 8.65 –1.93 11.35 –0.92 0.37
Montgomery-Åsberg Depression Rating Scale total score 14.48 7.94 –2.59 8.60 –1.62 0.12
Young Mania Rating Scale total score 4.24 3.54 1.21 5.48 1.19 0.25
Clinical Global Impression severity of illness score 3.76 1.12 0.10 1.23 0.45 0.66
Global Assessment of Functioning Scale, current score 41.90 11.33 5.93 12.85 2.49 0.02
a Patients having both a baseline measurement and at least one postbaseline measurement.
b Type III sum-of-squares ANCOVA model for change included terms for baseline value, treatment, and investigator.
c Change between baseline and endpoint, with the last observation carried forward.
TABLE 4. Changes in Vital Signs and Weight Among Patients With Prodromal Psychotic Symptoms During 1 Year of Treat-
ment With Olanzapine or Placebo and 1 Year of Follow-Up
Study Period, Measure, and Treatment Group
Baseline Change From Baselineb
Na Mean SD Mean SD
Double-blind treatment
Pulse, sitting (bpm)
Placebo group 29 74.72 11.40 –0.24 14.98
Olanzapine group 29 73.76 8.53 9.03 15.25
Pulse, standing (bpm)
Placebo group 29 85.41 12.83 2.62 19.22
Olanzapine group 28 81.39 13.44 9.50 17.56
Weight (kg)
Placebo group 29 69.98 17.05 0.30 4.24
Olanzapine group 30 69.12 17.91 8.79 9.05
No-treatment follow-up period
Pulse, sitting (bpm)
Former placebo group 8 80.38 7.43 –3.25 12.13
Former olanzapine group 9 84.33 11.02 –7.22 10.24
Pulse, standing (bpm)
Former placebo group 8 90.75 10.10 0.38 7.41
Former olanzapine group 9 94.78 11.25 –5.67 13.78
Weight (kg)
Former placebo group 8 63.16 9.74 2.16 4.97
Former olanzapine group 9 83.80 28.15 –6.46 5.32
a Patients having both a baseline measurement and at least one postbaseline measurement.
b Change between baseline and endpoint, with the last observation carried forward. Baseline for the follow-up period was the end of the treat-
ment period.
c With effects for treatment and investigator.
d Paired t test.
e Wilcoxon signed-rank test.
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1, 14, p=0.03). However, these laboratory changes were not
clinically meaningful. (Laboratory results are available
from the first author on request.) During study period 2,
the rates of two treatment-emergent adverse events were
significantly different in the two treatment groups. Fatigue
was reported by 29.0% of the patients in the olanzapine
group (nine of 31) and by 3.4% of the patients in the pla-
cebo group (one of 29) (p=0.01, Fisher’s exact test). In-
creased weight was noted by 61.3% of the olanzapine pa-
tients (N=19) and 17.2% of the placebo patients (N=5) (p=
0.001, Fisher’s exact test). During study period 3, there
were no significant differences between groups in the
treatment-emergent adverse events that occurred.
Table 4 presents findings on pulse and weight for both
study periods. The mean change in weight was signifi-
cantly greater in the olanzapine group than in the placebo
group during study period 2 and significantly lower
among the former olanzapine group than among the
former placebo group during study period 3. During study
period 2, the sitting pulse rate increased significantly in
Olanzapine (N=30)a
Between-Group 
AnalysisbBaseline Change From Baselinec
Paired t Test for Change 
Within Group
Mean SD Mean SD t (df=29) p F (df=1, 53) p
40.53 17.36 –6.73 17.17 –2.15 0.04 0.77 0.39
10.70 5.68 –3.50 5.78 –3.32 0.002 3.84 0.06
15.07 6.55 –1.27 6.38 –1.09 0.29 0.00 0.96
7.07 4.33 –1.07 4.05 –1.44 0.16 0.92 0.34
7.70 4.16 –0.90 3.66 –1.35 0.19 0.11 0.75
66.43 17.49 –4.50 22.12 –1.11 0.27 0.08 0.78
15.23 4.49 –1.63 5.65 –1.58 0.12 0.60 0.44
17.40 4.95 –0.43 6.55 –0.36 0.72 0.08 0.78
33.80 10.05 –2.43 12.07 –1.10 0.28 0.01 0.95
12.30 9.56 0.27 9.01 0.16 0.87 1.24 0.27
4.17 3.51 0.37 5.74 0.35 0.73 0.21 0.65
3.73 0.74 –0.10 1.06 –0.52 0.61 0.44 0.51
42.03 9.29 8.23 15.31 2.95 0.006 0.29 0.60
Analysis of Change From Baseline Between-Group Analysisc
td df Te p F df p
6.95 1, 53 0.01
–0.09 28 0.93
3.19 28 0.003
2.08 1, 52 0.16
0.73 28 0.47
2.86 27 0.008
21.58 1, 54 <0.001
0.38 28 0.71
5.32 29 <0.001
0.45 1, 14 0.51
–5.0 0.55
–14.5 0.09
1.06 1, 14 0.32
1.5 0.86
–9.5 0.30
11.04 1, 14 0.005
9.0 0.25
–22.5 0.004
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the olanzapine patients relative to the rate for the placebo
patients; no other significant between-group differences
in vital signs were observed.
Number Needed to Treat
The number needed to treat, calculated as the recipro-
cal of the absolute risk reduction (24), provides a clinically
useful measurement of the effect of preventive treatment
by determining the number of patients a clinician must
treat to prevent an adverse event (in this case, psychosis).
For our purposes, the number needed to treat was defined
as the number of prodromal patients who needed to be
treated with olanzapine to prevent conversion to psycho-
sis in the double-blind year. For this study, the number
needed to treat equaled 4.5.
Discussion
Study Elements
To our knowledge, this is the first double-blind, pla-
cebo-controlled trial that tested specific effects of an atyp-
ical antipsychotic on patients with prodromal symptoms
of schizophrenia. Also, it monitored patients with a scale
sensitive to attenuated schizophrenia-spectrum symp-
toms, thereby testing the efficacy of treatment for prodro-
mal symptom severity.
The patients were largely adolescent, male, functionally
compromised, and displaying symptoms similar to those
seen in psychosis but less severe and restrained by intact in-
sight. They provided little evidence of affective disturbance,
were almost completely free of substance abuse, and came
from families that were largely intact, that were often famil-
iar with mental illness, and that were concerned for their
struggling relative and motivated to find help. These char-
acteristics aided recruitment but also may have limited the
generalizability of the results to other at-risk populations.
Delaying or Preventing Psychosis
The study patients were at high risk, as 26.7% and 35.0%
developed psychosis by the end of the treatment year and
posttreatment year, respectively. In the treatment year
(study period 2), although not significantly different from
placebo, olanzapine had a lower rate of conversion to psy-
chosis (olanzapine: 16.1%, placebo: 37.9%) and a lower
hazard of converting to psychosis than the placebo group.
In study period 3, the conversion rates were not signifi-
cantly different (33.3% versus 25.0%). In comparison, sig-
nificantly fewer experimental (10%) than control (36%)
patients converted to psychosis in the first 6 months of the
trial reported by McGorry et al. (4).
Is the transition to psychosis delayed or prevented by
treatment? If olanzapine treatment is palliative and simply
delays onset (the way antipsychotics delay relapse in es-
tablished schizophrenia), then removing the drug should
result in a substantially increased rate of conversion. If
treatment truly prevents psychosis, then removing the
drug should not be followed by many (if any) conversions
to psychosis. Our study proved to be underpowered to an-
swer this question. In the no-treatment second year, only
17 patients remained in the trial. Five patients converted
to psychosis in the second year—three former olanzapine
patients (33.3%) and two former placebo patients (25.0%).
These numbers and rates are too small for meaningful
comparisons.
Two findings, nevertheless, suggest that we are seeing de-
lay, not prevention. First, if exposure to the drug is truly pre-
ventive, we would expect to find few, if any, former olanzap-
ine patients converting in study period 3. In fact, three of
nine patients (33.3%) did convert. Second, the prodromal
symptoms in the former olanzapine group returned to a sig-
nificantly higher level of severity when the drug was stopped.
Exacerbation of prodromal symptoms would not be ex-
pected if time-limited pre-onset treatment was truly preven-
tive.
We were surprised at how operationally benign the pro-
cess of conversion was. In all cases, patients with conver-
sion to psychosis accepted our judgment that open-label
drug treatment was necessary. They complied with treat-
ment without requiring hospitalization, missing signifi-
cant time from work or school, or disrupting their social
and familial networks. It may be that these patients were
able to make the transition smoothly because they had an
established relationship with us and because conversion
was declared at a point where loss of insight was recent
and irrational behaviors were still containable.
Reducing Prodromal Symptom Severity
Within their treatment group, the patients receiving
olanzapine had significant improvements during study
period 2 in the severity of positive and total prodromal
symptoms, a finding not seen within the placebo group.
Significant differences in positive prodromal symptoms
between groups (in favor of olanzapine) were also seen
from weeks 8 to 28 of the treatment year. It is possible that
after week 28 the remaining study groups contained
higher fractions of patients with false positive prodromes.
Our results cannot be compared directly with those of
McGorry et al. (4) because their design did not allow for
evaluation of treatment efficacy for symptoms.
Adverse Events
The most significant treatment-emergent adverse event
was weight gain. This replicates similar findings in pa-
tients suffering from schizophrenia. The weight gain in
our study, however, was greater than in a previous study
(25) and may relate to the low age of the subjects (26). As in
other studies of olanzapine, the rates of treatment-emer-
gent extrapyramidal symptoms were not significantly dif-
ferent between drug and placebo (27).
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Caveats and Implications for Research in the 
Prodrome
The limitations of this clinical trial include the lack of a
structured axis I assessment at baseline and follow-up and
the interrater reliability testing of the Structured Interview
for Prodromal Syndromes at only one site. Of importance
is that the study addressed an essentially new clinical en-
tity, which required designing new “prodromal” assess-
ment instruments and a new definition of psychosis onset.
Other limitations include the fact that our subjects were
recruited from families with high rates of mental illness,
restricting the ability to generalize the findings to other
populations. It is also possible that weight gain may have
revealed treatment assignment even though the raters
were blinded.
Clear and persistent problems emerged regarding re-
cruitment, group size, and power. Recruitment was diffi-
cult because a true positive prodrome is essentially an ear-
lier form of first-episode schizophrenia, the incidence of
which is uncommon. Furthermore, the public and treating
clinicians are largely unaware of this syndrome’s clinical
manifestations and referral possibilities. Compounding
the recruitment challenge is the variable fraction of pa-
tients with true versus false positive prodromes in each
“prodromal positive” study group. Studies of the natural
history of such subjects show different rates of conversion
and, therefore, the likely ratio of true to false positive at-
risk patients in each group. In such studies, conversion
rates have varied from 20% to 54% over periods of up to 2
years (3, 4, 8, 9, 12).
We originally estimated an overall first-year rate of con-
version to psychosis of 30% and hypothesized that twice
as many placebo-treated patients as olanzapine-treated
patients would convert. Power analysis with such parame-
ters suggested 180 patients (80% power) or 80 patients
(50% power). After 3.5 years of recruitment at four sites, we
stopped at 60 patients, which corresponded to 39% power
for testing treatment effects on transition to psychosis and
Patient Perspectives
Case 1: prodromal symptoms converting to psychosis dur-
ing placebo administration (true positive prodrome)
Andrew was a 16-year-old boy who was referred by his 
high school guidance counselor because of the recent devel-
opment of social withdrawal, conflicts with peers, and poor 
academic motivation. Andrew scored in the prodromal 
range on two dimensions: suspiciousness/persecutory idea-
tion and perceptual abnormalities/hallucinations. For 8 
months he had been feeling uncomfortable in crowds, 
thinking people might be making fun of him. He also began 
hearing distant buzzing noises and felt his mind was 
“playing tricks” on him. He was failing in school and was 
judged to be socially isolated, and he was given a Global As-
sessment of Functioning Scale score of 38.
Andrew met the study criteria for attenuated positive 
symptom prodromal syndrome. He was randomly assigned 
to placebo during double-blind treatment. He continued to 
report feeling that his siblings and his classmates were giv-
ing him a “hard time.” At month 2 he began avoiding eating 
lunch in the school cafeteria. By month 3 he became certain 
that kids at school wanted to hurt him, and he also began 
hearing his name being called by a voice he felt was real. He 
was judged to meet the study criteria for psychosis. Double-
blind medication was stopped, and open-label olanzapine 
was administered for 6 months.
Despite his mental state changes, Andrew continued as 
an outpatient and did not miss any school. His paranoia de-
creased in intensity during the first week of open-label olan-
zapine treatment, and it scored below the prodromal level 
by week 8. The voice calling his name became “fuzzy,” and 
this too relented by week 8. Andrew became more comfort-
able with his peers at school and more involved socially 
(e.g., in an after-school sports club) and academically (e.g., 
in an after-school tutorial). By the end of the study he re-
ceived a diagnosis of schizophreniform disorder, in remis-
sion.
Case 2: prodromal symptoms remitting during placebo ad-
ministration (false positive prodrome)
Benjamin was a 14-year-old boy whose parents sought 
help after hearing about the Prevention Through Risk Identi-
fication, Management, and Education clinic from a psychia-
trist who was assessing Benjamin for attentional disorder. 
Benjamin was not completing his homework, was disorgan-
ized, got into “trouble” at school, and was not changing his 
clothes. Discussing Benjamin’s development, his parents de-
scribed him as a shy, quiet, “good kid” who did well in 
school. The family history was positive for schizophrenia in a 
maternal sibling. At intake, Benjamin scored in the prodro-
mal range on three dimensions: suspiciousness/persecutory 
ideation, perceptual abnormalities/hallucinations, and con-
ceptual disorganization. He felt at times that kids at school 
might be talking about him. In the past year he had begun 
hearing ringing in his ears, seeing colored polka dots, and 
smelling things that others did not notice. These experiences 
occurred about once a month and were perplexing but not 
otherwise of concern. He talked monotonically, at times cir-
cumstantially, and occasionally lost his train of thought. He 
met the study criteria for the attenuated positive symptom 
prodromal syndrome.
Benjamin was randomly assigned to placebo, and he de-
veloped what appeared to be mild cogwheeling in his wrists, 
which remitted quickly with a dose of benztropine. Within 2 
months all of his prodromal symptoms no longer scored in 
the prodromal window of severity. His symptoms were 
judged to be remitted for the rest of the year of double-
blind treatment. He continued to improve symptomatically, 
academically, and socially in the second, no-treatment year. 
At discharge, he received a diagnosis of prodromal syn-
drome, in remission.
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on prodromal symptom severity. It also meant insufficient
power to test whether the treatment was palliative versus
preventive. Furthermore, because of the high dropout rate
during the trial and the fact that the conversions to psy-
chosis did not occur at the same time points, the a priori
plan to use a Fisher exact test to assess the treatment dif-
ference in the rates of conversion to psychosis was not ap-
propriate for the final data. Therefore, the results from the
treatment comparisons based on the Fisher exact test
should be interpreted with caution and should be supple-
mented with the results from the post hoc analysis with
the Cox proportional hazards model.
It is striking that all of the olanzapine patients whose
symptoms converted to psychosis did so within the first 4
weeks of the clinical trial. These patients were among the
most symptomatic, suggesting several possibilities. First,
some of these patients may have been misclassified as pro-
dromal when they were psychotic, especially because pa-
tients may be reluctant to discuss psychotic symptoms on
initial evaluation. It is possible that some patients were al-
ready psychotic but unable to communicate this until, par-
adoxically, they received sufficient olanzapine to convey ef-
fectively their state of mind. Finally, some of these patients
may have been on the cusp of psychosis and were not med-
icated rapidly or sufficiently enough to forestall conversion.
Further studies are clearly needed to replicate and ex-
tend our findings, which suggest strategies for future re-
search of this type. First, ongoing compliance should be
monitored carefully and should include blood tests to de-
termine the drug levels in converting patients at the time
of conversion. Second, it may be prudent to design 2- to 4-
week placebo or no-treatment lead-in periods before ran-
domization, excluding patients who meet the criteria for
being psychotic within this period. Third, future studies
should use larger study groups and longer assessment
times to determine whether a medication could prevent
psychosis onset if continued for longer than 1 year.
Fourth, power should be enhanced by 1) determination of
further markers of risk for psychosis to improve the identi-
fication of the truly at-risk subset of any clinically “prodro-
mal” subject group or 2) collaboration among multiple
sites and pooling of subjects (28).
Conclusions
Although the primary objective of demonstrating a sig-
nificant treatment difference in the rate of conversion to
psychosis was not met, the nearly significant difference
between treatment groups in the conversion rate points to
the possibility that olanzapine might reduce the rate of
conversion to psychosis and delay the onset of psychosis.
For estimating benefit, the number needed to treat of 4.5
suggests that between four and five persons meeting the
criteria for prodromal symptoms need to be treated in or-
der to prevent one conversion to psychosis over the 1 year
of treatment. This is comparable in magnitude to the
number needed to treat reported in the clinical trial of ris-
peridone and cognitive behavior intervention by McGorry
et al. (4). For estimating risk, the treated patients will gain
an average of 13% in body weight in the first year, but they
will not display blood laboratory values suggestive of risk
for diabetes or cardiovascular disease. Being heavier, these
young people may be at higher long-term risk for the met-
abolic syndrome, but they do not display this during the
first year of treatment. Ratios of longer-term benefit and
risk require more clinical trials with variable durations of
clinical exposure.
Overall, we feel that this clinical trial demonstrates that
the benefits of pre-onset identification and treatment out-
weigh the risks to a degree sufficient to endorse future
clinical trials (in academic centers with programs for early
detection and intervention in psychosis) so that definitive
recommendations on use of antipsychotics to treat the
prodromal phase of schizophrenia can be made.
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